Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

DigiSight Technologies Inc.'s cloud-based Paxos platform enables patients with acute ophthalmic conditions to self-administer 10 functional tests, ranging from visual acuity to color discrimination, using an application on a smartphone, tablet or other mobile device.

In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.